Confirmed Sponsors & Exhibitors
The ISDE 2023 World Congress would like to thank the following companies for their support:
DIAMOND SPONSOR
GOLD SPONSOR
SILVER SPONSORS
SUPPORTERS
Supported by an Educational Grant from Cook Medical
EXHIBITORS
CASTLE BIOSCIENCES
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first.
Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. Visit www.castletestinfo.com to learn more.
CASTLE BIOSCIENCES
CDx DIAGNOSTICS
CDx Diagnostics, provider of WATS3D, is a pioneer in the detection of Barrett’s esophagus and esophageal dysplasia. The company’s mission of “Empowering Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time” is accomplished by WATS3D - a proprietary 3-in-1 diagnostic platform consists of unique tissue sampling, better disease identification via an AI algorithm and proprietary Extended Depth of Focus, and diagnosis by CDx expert GI pathologists.
WATS3D has received a recommendation from the ASGE Standards of Practice Guidelines, and several recognitions from medical professional society organizations. It is easy to integrate WATS3D into daily endoscopic workflow. Routine clinical use of CDx testing has already identified thousands of precancers that would otherwise have been missed in time for effective treatment.
CDx DIAGNOSTICS
ELLODI PHARMACEUTICALS
Ellodi Pharmaceuticals is a gastroenterology-focused specialty pharmaceutical company developing novel therapies for the treatment of Eosinophilic Esophagitis.
ELLODI PHARMACEUTICALS
IMPLANTICA-REFLUXSTOP
Implantica is a MedTech company dedicated to bringing advanced technology into the body. The Company’s lead product RefluxStop™ is a passive implant that treats the cause of acid reflux, a treatment field with over 1 billion sufferers.
RefluxStop’s™ innovative technology has the potential to spur a paradigm shift in anti-reflux surgical treatment. It’s unique mechanism of action differentiates it from the standard of care and current surgical solutions. This is because the older methods focused on the Lower Esophageal Sphincter (LES) and encircle the food passageway to support the closing ring muscle. RefluxStop™ addresses acid reflux without affecting the food passageway. Learn more at www.implantica.com.
IMPLANTICA-REFLUXSTOP
INTUITIVE SURGICAL
Intuitive is a global leader in minimally invasive care and the pioneer of robotic surgery.
INTUITIVE SURGICAL
OLYMPUS
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries.
As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients.
More information available on www.olympusprofed.com and www.olympusamerica.com/ca.
OLYMPUS
Proteomics International
Proteomics International (ASX: PIQ) is a medical technology company at the forefront of predictive diagnostics, pharmacokinetic and bio-analytical services, founded in Western Australia in 2001. The Company is recognised as a specialist in the area of proteomics – the industrial-scale study of structure and function of proteins. Proteomics International is dedicated to enhancing the quality of life by developing and applying innovative tools that enable the improved treatment of disease. proteomics.com.au
Proteomics International
Exhibitors
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries.
As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients.
Implantica is a MedTech company dedicated to bringing advanced technology into the body. The Company’s lead product RefluxStop™ is a passive implant that treats the cause of acid reflux, a treatment field with over 1 billion sufferers.
RefluxStop’s™ innovative technology has the potential to spur a paradigm shift in anti-reflux surgical treatment. It’s unique mechanism of action differentiates it from the standard of care and current surgical solutions. This is because the older methods focused on the Lower Esophageal Sphincter (LES) and encircle the food passageway to support the closing ring muscle. RefluxStop™ addresses acid reflux without affecting the food passageway.
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping patients and clinicians first. Our innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes.
CDx Diagnostics, provider of WATS3D, is a pioneer in the detection of Barrett’s esophagus and esophageal dysplasia. The company’s mission of “Empowering Physicians with Innovative Technology to Prevent Esophageal Cancer, One Patient at a Time” is accomplished by WATS3D – a proprietary 3-in-1 diagnostic platform consists of unique tissue sampling, better disease identification via an AI algorithm and proprietary Extended Depth of Focus, and diagnosis by CDx expert GI pathologists. WATS3D has received a recommendation from the ASGE Standards of Practice Guidelines, and several recognitions from medical professional society organizations. It is easy to integrate WATS3D into daily endoscopic workflow. Routine clinical use of CDx testing has already identified thousands of precancers that would otherwise have been missed in time for effective treatment.